I do not know why there are only a few posts about
Post# of 148235
My takeaways/ interpretation:
Cancer:
1. Dosage study showed a 23 fold increase of efficiency regarding CTC from 350mg to 700mg! (Why did they not explain this in simple words in the 2300% PR?)
2. The mixture of 350mg and 700mg patients showed results as good as SOC or superiority against SOC. How good will "700mg only" dosage perform against SOC?
3. BTD for brain metastasis will follow soon with very strong cases.
NASH:
1. It seems 350mg open label patients hit already primary and secondary endpoints! How will the data for 700mg be if LL scales like in the NASH trial??
I cannot wait for the Topline report of the 60 patients double blinded placebo trial!